Biopharma Transcript

AtriCure, Inc. ATRC

Nasdaq · cardio-renal-metabolic · device-combination · EDGAR · Updated Oct 24, 2026

AtriCure, Inc. (Nasdaq: ATRC) is a cardio-renal-metabolic medical device company. Its next catalyst on record is AtriClip FLEX-Mini and PRO-Mini: Launch in Europe following CE mark under EU MDR (2026).

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Next further out: AtriClip FLEX-Mini and PRO-Mini — Launch in Europe following CE mark under EU MDR (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.

Pipeline

ProgramIndicationModalityStage
AtriClip LAA Exclusion System (LeAAPS IDE trial)Prophylactic stroke reduction in cardiac surgery patientsdevice-combinationNA_NON_THERAPEUTIC
BoxX-NoAF IDE trial (EnCompass clamp plus AtriClip)Prevention of post-operative AF in non-AF patientsdevice-combinationNA_NON_THERAPEUTIC
HEAL-IST (Isolator Synergy)Inappropriate sinus tachycardiadevice-combinationNA_NON_THERAPEUTIC
AtriClip FLEX-Mini and PRO-Mini (EU launch)LAA exclusiondevice-combinationNA_NON_THERAPEUTIC

For subscribers

Other cardio-renal-metabolic companies